Skip to main content
Clinical Trials/NCT02770560
NCT02770560
Completed
Not Applicable

Efficacy of Urokinase Containing Locking Solutions for Thrombotic Dysfunction of Tunneled Cuffed Catheters : a Single-center Retrospective Study

Universitair Ziekenhuis Brussel1 site in 1 country148 target enrollmentMay 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Kidney Failure, Chronic
Sponsor
Universitair Ziekenhuis Brussel
Enrollment
148
Locations
1
Primary Endpoint
Change in catheter blood flow (expressed in ml/min) after Urokinase-containing locking solution
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Thrombotic dysfunction is a common complication of tunneled cuffed catheters (TCC) leading to inadequate dialysis dose, need to catheter replacement with as consequence progressive exclusion of vascular sites. Thrombolytic agent can be used as therapeutic locking solution to dissolve the clotting formed in of around the catheter lumen. There are few studies on the optimal approach of TCC-related thrombosis with thrombolytic containing locking solution (dose, number of administrations, timing of administration - intra or interdialytic use). The primary objective of this retrospective study was to compare the efficacy of inter versus intradialytic Urokinase containing locking solution on restoration of the TCC blood flow. The investigators also assess the question of multiple administrations of Urokinase are more efficient than one single administration

Registry
clinicaltrials.gov
Start Date
May 2010
End Date
November 2014
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Hemodialysis patients over 18 years old, receiving hemodialysis between 1st May 2010 and 31st October 2014 via a tunneled cuffed catheter at the Hemodialysis Unit of Universitair Ziekenhuis Brussel Hospital.

Exclusion Criteria

  • Patients younger than 18 years old
  • Patients with a temporary dialysis catheter
  • Patients who never received a tunneled hemodialysis catheter in this period
  • Patients who didn't have a medical file at the Universitair Ziekenhuis Brussel Hospital

Outcomes

Primary Outcomes

Change in catheter blood flow (expressed in ml/min) after Urokinase-containing locking solution

Time Frame: up to 54 months

Comparison of catheter blood flow measurement before and after Urokinase locking solution administration according to the type of Urokinase prescription (inter- versus intra-dialytic use, one- single versus multiple administrations)

Change of pump pressures (expressed in mmHg) after Urokinase-containing locking solution

Time Frame: up to 54 months

Comparison of pump pressures measurement before and after Urokinase locking solution administration according to the type of prescription of Urokinase containing locking solution (inter versus intra-dialytic, one single use versus multiple administrations)

Study Sites (1)

Loading locations...

Similar Trials